Mr. Hugh Rogers reports

BIONXT REPORTS EXPANDED RESEARCH, DEVELOPMENT AND COMMERCIALIZATION CAPABILITY WITH CENTRALIZED MUNICH LABORATORY

Bionxt Solutions Inc. has integrated its research, development and commercialization activities to the Gen-Plus GmbH & Co. KG, a contract research and development organization (CRDO) in Munich, Germany. The move provides Bionxt with enhanced R&D (research and development) capabilities, collaboration opportunities, and accelerated innovation potential within a major European biotech hub.

The company seeks to leverage the advanced and innovative infrastructure of the Gen-Plus laboratory and harness the facility's 1,000 square metres of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant (good manufacturing practice) processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower Bionxt to maximize the potential of its proprietary drug delivery systems, neurodegenerative disease therapeutics and next-generation biomedical technologies.

In the coming weeks, Bionxt and Gen-Plus will be working together closely and focused on the development and commercialization of the company's lead product, BNT23001, a sublingual thin-film formulation of cladribine for the treatment of multiple sclerosis (MS). Preparation activities for the planned human bioequivalence study include placebo trials, product and technology transfer, upscaling of manufacturing, and analytical validation of the active pharmaceutical ingredient.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC Markets under the symbol BNXTF and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.